Delivery Order SPE2DB24D9230-SPE2DB25FHVPJ

Award Date 1/10/25
Potential Completion Date 1/13/25
Potential Value $13K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $12,934.05, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,508.77 contract is for the delivery of XTANDI 80 MG TABLET 60S, a specialized prescription medication, to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, valued at $21,556.75, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a delivery order for 4,565,148,507 units of the pharmaceutical product XTANDI 40 MG CAPSULE 120S, with a completion date of July 16, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
This federal contract award, valued at $12,934.05, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of 4566811681 - XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This federal contract award, valued at $8,622.72, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This federal contract award, valued at $4,169.59, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a delivery order for the pharmaceutical product XTANDI 40 MG TABLET 120S, with a period of performance through December 3, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at $499,999,999...
This federal contract award, valued at $8,339.18, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the provision of XTANDI 80 MG TABLET 60S, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,508.77 firm fixed-price delivery order is for the supply of XTANDI 40 MG TABLET 120S, a pharmaceutical product. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the DLA to issue...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $4,169.59, is a firm fixed-price delivery order for the supply of XTANDI 40 MG TABLET 120S. DMS Pharmaceutical Group Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This...
This federal contract award, valued at $8,339.18, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award is a delivery order under a larger indefinite delivery contract (IDC) with a ceiling value of up to $499,999,999 that allows DLA to issue firm fixed-price orders for a comprehensive range of pharmaceutical items to support the recurring medical supply needs of military...
  • SPE2DB24D9230
    Indefinite Delivery Contract
  • SPE2DB24D9230-SPE2DB25FHVPJ
    Delivery Order

This federal contract award, valued at $12,508.77, was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the pharmaceutical product XTANDI 80 MG TABLET 60S, with a completion date of January 13, 2025.

DMS Pharmaceutical Group Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables.

This contract award is not associated with any set-aside designation, allowing DMS Pharmaceutical Group Inc. to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains. The company has consistently demonstrated its capability to provide a diverse array of pharmaceutical products to the DLA through its previous contract awards.

Generated 4/11/25, 11:20 AM